Inactive Instrument
IRLAB Therapeutics AB Share Price Nasdaq Stockholm
Stocks
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Nasdaq Stockholm
|
||
| - SEK | - |
|
| 10-27 | Irlab Therapeutics Set to Obtain US Patent for Parkinson's Disease Drug Candidate | MT |
| 10-27 | Irlab receives positive patent notice in the US for IRL1117 | FW |
| Market Cap | 311M 31.64M 28.33M 26.06M 23.62M 44.14M 3B 44.97M 125M 1.58B 119M 116M 4.98B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 311M 31.64M 28.33M 26.06M 23.62M 44.14M 3B 44.97M 125M 1.58B 119M 116M 4.98B | EV / Sales 2026 * |
3.07x | EV / Sales 2027 * | 2.17x |
| Free-Float |
83.4% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/07/2024 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 31/12/2012 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 31/12/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 31/12/2015 |
| Chairman | 73 | 06/05/2020 | |
Veronica Wallin
BRD | Director/Board Member | 40 | 31/12/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.19% | +11.31% | +64.28% | +155.66% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +83.74% | 658B | |
| +1.41% | +3.24% | +35.25% | +106.98% | 521B | |
| -1.65% | +0.10% | +52.95% | +66.66% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.38% | 369B | |
| -1.73% | +3.12% | +32.12% | +55.28% | 307B | |
| -1.56% | +7.08% | +11.32% | +32.83% | 290B | |
| +1.15% | +6.09% | +56.15% | +78.66% | 252B | |
| +3.06% | +9.38% | +42.48% | +112.84% | 212B | |
| Average | -0.13% | +5.90% | +45.90% | +82.00% | 473.55B | |
| Weighted average by Cap. | -0.41% | +6.60% | +50.01% | +98.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 101M 10.3M 9.23M 8.49M 7.69M 14.37M 978M 14.64M 40.62M 515M 38.66M 37.84M 1.62B | 143M 14.58M 13.05M 12.01M 10.88M 20.34M 1.38B 20.72M 57.49M 728M 54.7M 53.54M 2.3B |
| Net income | -36.1M -3.67M -3.29M -3.03M -2.74M -5.13M -349M -5.22M -14.49M -184M -13.79M -13.5M -579M | 34.6M 3.52M 3.15M 2.9M 2.63M 4.91M 334M 5.01M 13.89M 176M 13.22M 12.94M 555M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Calendar
Select your edition
All financial news and data tailored to specific country editions
